相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Fibroblast growth factor 23: state of the field and future directions
Nisan Bhattacharyya et al.
TRENDS IN ENDOCRINOLOGY AND METABOLISM (2012)
Safety and Efficacy of Intravenous Ferric Carboxymaltose (750 mg) in the Treatment of Iron Deficiency Anemia: Two Randomized, Controlled Trials
Charles F. Barish et al.
ANEMIA (2012)
Effect of Intravenous Saccharated Ferric Oxide on Serum FGF23 and Mineral Metabolism in Hemodialysis Patients
Yoko Takeda et al.
AMERICAN JOURNAL OF NEPHROLOGY (2011)
FERGIcor, a Randomized Controlled Trial on Ferric Carboxymaltose for Iron Deficiency Anemia in Inflammatory Bowel Disease
Rayko Evstatiev et al.
GASTROENTEROLOGY (2011)
Iron Modifies Plasma FGF23 Differently in Autosomal Dominant Hypophosphatemic Rickets and Healthy Humans
Erik A. Imel et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2011)
A randomized controlled trial comparing intravenous ferric carboxymaltose with oral iron for treatment of iron deficiency anaemia of non-dialysis-dependent chronic kidney disease patients
Wajeh Y. Qunibi et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2011)
Iron deficiency drives an autosomal dominant hypophosphatemic rickets (ADHR) phenotype in fibroblast growth factor-23 (Fgf23) knock-in mice
Emily G. Farrow et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
FGF-23: More Than a Regulator of Renal Phosphate Handling?
Harald Jueppner et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2010)
Severe Hypophosphatemia After Intravenous Administration of Iron Carboxymaltose in a Stable Renal Transplant Recipient
Laila-Yasmin Mani et al.
TRANSPLANTATION (2010)
Ferric Carboxymaltose A Review of its Use in Iron-Deficiency Anaemia
Katherine A. Lyseng-Williamson et al.
DRUGS (2009)
FGF23 Elevation and Hypophosphatemia after Intravenous Iron Polymaltose: A Prospective Study
Belinda J. Schouten et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2009)
Large-dose intravenous ferric carboxymaltose injection for iron deficiency anemia in heavy uterine bleeding: a randomized, controlled trial
David B. Van Wyck et al.
TRANSFUSION (2009)
Iron polymaltose-induced FGF23 elevation complicated by hypophosphataemic osteomalacia
Belinda J. Schouten et al.
ANNALS OF CLINICAL BIOCHEMISTRY (2009)
A novel intravenous iron formulation for treatment of anemia in inflammatory bowel disease:: The ferric carboxymaltose (FERINJECT®) randomized controlled trial
Stefanie Kulnigg et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2008)
Ferric carboxymaltose injection in the treatment of postpartum iron deficiency anemia: a randomized controlled clinical trial
Melvin H. Seid et al.
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY (2008)
Comparative efficacy and safety of intravenous ferric carboxymaltose in the treatment of postpartum iron deficiency anemia
Christian Breymann et al.
INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS (2008)
Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis
Orlando M. Gutierrez et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Intravenous ferric carboxymaltose compared with oral iron in the treatment of postpartum anemia - A randomized controlled trial
David B. Van Wyck et al.
OBSTETRICS AND GYNECOLOGY (2007)
Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers
T Larsson et al.
KIDNEY INTERNATIONAL (2003)
Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia
T Shimada et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
分享论文
